ContractTechnology Transfer Agreement • August 11th, 2008 • Unigene Laboratories Inc • Medicinal chemicals & botanical products • Hong Kong
Contract Type FiledAugust 11th, 2008 Company Industry JurisdictionPortions of this Exhibit were omitted and filed separately with the Secretary of the Commission pursuant to an application for confidential treatment filed with the Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934. Such omissions are designated as ***.
AGREEMENT OF ASSIGNMENTAgreement of Assignment • August 11th, 2008 • Unigene Laboratories Inc • Medicinal chemicals & botanical products
Contract Type FiledAugust 11th, 2008 Company IndustryIt is unanimously agreed between Parties A, B and C to assign all rights, responsibilities and obligations of Party A without reservation to Party C manifested in, including but not limited to, the following documents:
AGREEMENT BETWEEN SHIJIAZHUANG PHARMACEUTICAL GROUP COMPANY, LTD. AND UNIGENE LABORATORIES, INC.Joint Venture Agreement • August 11th, 2008 • Unigene Laboratories Inc • Medicinal chemicals & botanical products
Contract Type FiledAugust 11th, 2008 Company IndustryThis Agreement (the “Agreement”), dated as of April 23, 2008, is entered into by Shijiazhuang Pharmaceutical Group Company, Ltd., a legal person established under the laws of the People’s Republic of China (“SPG”), and Unigene Laboratories, Inc., a corporation under the laws of the State of Delaware in the United States (“Unigene”).
AMENDMENT NO. 6 TO LICENSE AGREEMENT DATED AS OF APRIL 13, 2002 BY AND BETWEEN UNIGENE LABORATORIES, INC. AND SMITHKLINE BEECHAM CORPORATIONLicense Agreement • August 11th, 2008 • Unigene Laboratories Inc • Medicinal chemicals & botanical products • Pennsylvania
Contract Type FiledAugust 11th, 2008 Company Industry JurisdictionThis Amendment No. 6 (“Amendment No. 6”) dated as of April 9, 2008 (the “Amendment Date”) to the License Agreement dated as of April 13, 2002, as amended on January 27, 2007, January 16, 2003, October 14, 2003, May 27, 2004 and September 23, 2004 (referred to hereinafter as the “Agreement”) by and between Unigene Laboratories, Inc. (“Unigene”), a Delaware corporation, and SmithKline Beecham Corporation, a GlaxoSmithKline Company (“GSK”), a Pennsylvania corporation.